Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Sci Immunol ; 2(12)2017 Jun 16.
Article in English | MEDLINE | ID: mdl-28783662

ABSTRACT

CD4+FOXP3+ regulatory T (Treg) cells are critical mediators of immune tolerance, and their deficiency owing to FOXP3 mutations in immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) patients results in severe autoimmunity. Different FOXP3 mutations result in a wide range of disease severity, reflecting the relative importance of the affected residues in the integrity of the FOXP3 protein and its various molecular interactions. We characterized the cellular and molecular impact of the most common IPEX mutation, p.A384T, on patient-derived Treg cells. We found that the p.A384T mutation abrogated the suppressive capacity of Treg cells while preserving FOXP3's ability to repress inflammatory cytokine production. This selective functional impairment is partly due to a specific disruption of FOXP3A384T binding to the histone acetyltransferase Tat-interacting protein 60 (TIP60) (KAT5) and can be corrected using allosteric modifiers that enhance FOXP3-TIP60 interaction. These findings reveal the functional impact of TIP60 in FOXP3-driven Treg biology and provide a potential target for therapeutic manipulation of Treg activity.

2.
Arthritis Res Ther ; 16(5): 461, 2014 Oct 02.
Article in English | MEDLINE | ID: mdl-25273676

ABSTRACT

INTRODUCTION: Lysophosphatidic acid (LPA) is a bioactive lipid that binds to G protein-coupled receptors (LPA1-6). Recently, we reported that abrogation of LPA receptor 1 (LPA1) ameliorated murine collagen-induced arthritis, probably via inhibition of inflammatory cell migration, Th17 differentiation and osteoclastogenesis. In this study, we examined the importance of the LPA-LPA1 axis in cell proliferation, cytokine/chemokine production and lymphocyte transmigration in fibroblast-like synoviocytes (FLSs) obtained from the synovial tissues of rheumatoid arthritis (RA) patients. METHODS: FLSs were prepared from synovial tissues of RA patients. Expression of LPA1-6 was examined by quantitative real-time RT-PCR. Cell surface LPA1 expression was analyzed by flow cytometry. Cell proliferation was analyzed using a cell-counting kit. Production of interleukin 6 (IL-6), vascular endothelial growth factor (VEGF), chemokine (C-C motif) ligand 2 (CCL2), metalloproteinase 3 (MMP-3) and chemokine (C-X-C motif) ligand 12 (CXCL12) was measured by enzyme-linked immunosorbent assay. Pseudoemperipolesis was evaluated using a coculture of RA FLSs and T or B cells. Cell motility was examined by scrape motility assay. Expression of adhesion molecules was determined by flow cytometry. RESULTS: The expression of LPA1 mRNA and cell surface LPA1 was higher in RA FLSs than in FLSs from osteoarthritis tissue. Stimulation with LPA enhanced the proliferation of RA FLSs and the production of IL-6, VEGF, CCL2 and MMP-3 by FLSs, which were suppressed by an LPA1 inhibitor (LA-01). Ki16425, another LPA1 antagonist, also suppressed IL-6 production by LPA-stimulated RA FLSs. However, the production of CXCL12 was not altered by stimulation with LPA. LPA induced the pseudoemperipolesis of T and B cells cocultured with RA FLSs, which was suppressed by LPA1 inhibition. In addition, LPA enhanced the migration of RA FLSs and expression of vascular cell adhesion molecule and intercellular adhesion molecule on RA FLSs, which were also inhibited by an LPA1 antagonist. CONCLUSIONS: Collectively, these results indicate that LPA-LPA1 signaling contributes to the activation of RA FLSs.


Subject(s)
Fibroblasts/drug effects , Lysophospholipids/pharmacology , Receptors, Lysophosphatidic Acid/metabolism , Synovial Membrane/metabolism , Aged , Aged, 80 and over , Animals , Arthritis, Rheumatoid/genetics , Arthritis, Rheumatoid/metabolism , Arthritis, Rheumatoid/pathology , CHO Cells , Cell Movement/drug effects , Cell Proliferation/drug effects , Cell Proliferation/genetics , Cells, Cultured , Cricetinae , Cricetulus , Cytokines/metabolism , Enzyme-Linked Immunosorbent Assay , Fibroblasts/metabolism , Fibroblasts/pathology , Gene Expression/drug effects , Humans , Inflammation Mediators/metabolism , Isoxazoles/pharmacology , Leukocytes/drug effects , Middle Aged , Propionates/pharmacology , Receptors, Lysophosphatidic Acid/antagonists & inhibitors , Receptors, Lysophosphatidic Acid/genetics , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/drug effects , Signal Transduction/genetics , Synovial Membrane/pathology
3.
Arthritis Rheumatol ; 66(10): 2751-61, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24943093

ABSTRACT

OBJECTIVE: We previously reported that blockade of the Notch ligand delta-like protein 1 (DLL-1) suppressed osteoclastogenesis and ameliorated arthritis in a mouse model of rheumatoid arthritis (RA). However, the mechanisms by which joint inflammation were suppressed have not yet been revealed. This study was undertaken to determine whether DLL-1 regulates the production of RA-related proinflammatory cytokines. METHODS: Joint cells from mice with collagen-induced arthritis (CIA) and mouse fibroblast-like synoviocytes (FLS) were cultured with or without stimuli in the presence of neutralizing antibodies against Notch ligands, and the production of proinflammatory cytokines was determined by enzyme-linked immunosorbent assay. The expression of Notch receptors and ligands on mouse joint cells was determined by flow cytometry. RESULTS: The production of interleukin-6 (IL-6) and granulocyte-macrophage colony-stimulating factor (GM-CSF) by mouse joint cells with or without stimulation was suppressed by DLL-1 blockade. DLL-1 blockade also suppressed the levels of IL-6 and matrix metalloproteinase 3 (MMP-3) in the joint fluid in a mouse model of RA. However, the production of tumor necrosis factor α and IL-1ß was not suppressed by DLL-1 blockade. The production of IL-6 and MMP-3 by mouse FLS was enhanced by DLL-1 stimulation as well as Notch-2 activation. Among joint cells, DLL-1 was not expressed on mouse FLS but was expressed on macrophages. CONCLUSION: These results suggest that the interaction of DLL-1 on mouse joint macrophages with Notch-2 on mouse FLS enhances the production of IL-6 and MMP-3. Therefore, suppression of IL-6, GM-CSF, and MMP-3 production by DLL-1 blockade might be responsible for the amelioration of arthritis in a mouse model of RA.


Subject(s)
Arthritis, Experimental/metabolism , Arthritis, Rheumatoid/metabolism , Intercellular Signaling Peptides and Proteins/metabolism , Interleukin-6/metabolism , Matrix Metalloproteinase 3/metabolism , Synovial Membrane/metabolism , Animals , Calcium-Binding Proteins , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Joints/metabolism , Male , Mice , Mice, Inbred DBA , Synovial Fluid/metabolism
4.
Arthritis Res Ther ; 14(2): R45, 2012 Mar 05.
Article in English | MEDLINE | ID: mdl-22390640

ABSTRACT

INTRODUCTION: Osteoclastogenesis plays an important role in the bone erosion of rheumatoid arthritis (RA). Recently, Notch receptors have been implicated in the development of osteoclasts. However, the responsible Notch ligands have not been identified yet. This study was undertaken to determine the role of individual Notch receptors and ligands in osteoclastogenesis. METHODS: Mouse bone marrow-derived macrophages or human peripheral blood monocytes were used as osteoclast precursors and cultured with receptor activator of nuclear factor-kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) to induce osteoclasts. Osteoclasts were detected by tartrate-resistant acid phosphatase (TRAP) staining. K/BxN serum-induced arthritic mice and ovariectomized mice were treated with anti-mouse Delta-like 1 (Dll1) blocking monoclonal antibody (mAb). RESULTS: Blockade of a Notch ligand Dll1 with mAb inhibited osteoclastogenesis and, conversely, immobilized Dll1-Fc fusion protein enhanced it in both mice and humans. In contrast, blockade of a Notch ligand Jagged1 enhanced osteoclastogenesis and immobilized Jagged1-Fc suppressed it. Enhancement of osteoclastogenesis by agonistic anti-Notch2 mAb suggested that Dll1 promoted osteoclastogenesis via Notch2, while suppression by agonistic anti-Notch1 mAb suggested that Jagged1 suppressed osteoclastogenesis via Notch1. Inhibition of Notch signaling by a gamma-secretase inhibitor suppressed osteoclastogenesis, implying that Notch2/Dll1-mediated enhancement was dominant. Actually, blockade of Dll1 ameliorated arthritis induced by K/BxN serum transfer, reduced the number of osteoclasts in the affected joints and suppressed ovariectomy-induced bone loss. CONCLUSIONS: The differential regulation of osteoclastogenesis by Notch2/Dll1 and Notch1/Jagged1 axes may be a novel target for amelioration of bone erosion in RA patients.


Subject(s)
Calcium-Binding Proteins/physiology , Intercellular Signaling Peptides and Proteins/physiology , Membrane Proteins/physiology , Osteoclasts/physiology , Receptor, Notch1/physiology , Receptor, Notch2/physiology , Animals , Arthritis, Experimental/metabolism , Arthritis, Experimental/pathology , Cell Differentiation , Cells, Cultured , Cricetinae , Female , Humans , Jagged-1 Protein , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Serrate-Jagged Proteins
5.
Biochem Biophys Res Commun ; 418(4): 799-805, 2012 Feb 24.
Article in English | MEDLINE | ID: mdl-22310713

ABSTRACT

Notch plays multiple roles in T cell development in the thymus and T cell differentiation in the periphery. In order to systematically examine the role of Notch in T cell biology, we determined the cell surface expression of all Notch receptors and ligands on various populations of T cells by using a panel of specific monoclonal antibodies we recently established. Notch1 and Notch3 were upregulated at double-negative (DN) 2-DN4 stages of immature thymocytes, then downregulated on mature single-positive thymocytes and peripheral T cells, but were rapidly upregulated again upon activation. Notch2 was consistently expressed on T cells while Notch4 was not. Jagged1 and Jagged2 were expressed at double-positive stage of immature T cells. Jagged2 was also inducible on mature T cells upon activation. In contrast, no Delta-like (Dll) 1 or Dll4 expression was observed on T cells. These comprehensive profiling of the expression of Notch receptors and ligands would be informative to fully understand the role of individual Notch receptors and ligands in T cell development and differentiation.


Subject(s)
Receptors, Notch/metabolism , T-Lymphocytes/metabolism , Animals , Antibodies, Monoclonal/chemistry , Calcium-Binding Proteins/analysis , Calcium-Binding Proteins/metabolism , Intercellular Signaling Peptides and Proteins/analysis , Intercellular Signaling Peptides and Proteins/metabolism , Intracellular Signaling Peptides and Proteins/analysis , Intracellular Signaling Peptides and Proteins/metabolism , Jagged-1 Protein , Jagged-2 Protein , Ligands , Membrane Proteins/analysis , Membrane Proteins/metabolism , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Receptors, Notch/analysis , Serrate-Jagged Proteins , T-Lymphocyte Subsets/chemistry , T-Lymphocyte Subsets/metabolism , T-Lymphocytes/chemistry
6.
Int Immunol ; 21(3): 295-301, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19181931

ABSTRACT

The importance of Notch signaling to maintain CD8- dendritic cells (DCs) in the spleen has recently been revealed. However, the ligand responsible for this Notch signaling has not been determined yet. In this study, we demonstrated that blocking of Delta-like (Dll) 1 alone had no significant effect on the maintenance of CD8- DCs while marginal zone (MZ) B cells were significantly reduced in the spleen of mice. On the other hand, blocking of Dll1, Dll4, Jagged1 and Jagged2 significantly decreased CD8- DCs. All these Notch ligands are expressed predominantly in the red pulp of the spleen where CD8- DCs reside. These results indicate a differential regulation of CD8- DCs and MZ B cells by Notch ligands in the spleen.


Subject(s)
B-Lymphocytes/metabolism , Calcium-Binding Proteins/metabolism , Dendritic Cells, Follicular/metabolism , Intercellular Signaling Peptides and Proteins/metabolism , Membrane Proteins/metabolism , Receptors, Notch/metabolism , Spleen/metabolism , Animals , Antibodies, Blocking/administration & dosage , B-Lymphocytes/immunology , CD8 Antigens , Calcium-Binding Proteins/genetics , Calcium-Binding Proteins/immunology , Cell Count , Dendritic Cells, Follicular/immunology , Gene Expression Regulation , Intercellular Signaling Peptides and Proteins/genetics , Intercellular Signaling Peptides and Proteins/immunology , Interleukin-12/metabolism , Jagged-1 Protein , Jagged-2 Protein , Membrane Proteins/genetics , Membrane Proteins/immunology , Mice , Mice, Inbred C57BL , Receptors, Notch/genetics , Receptors, Notch/immunology , Serrate-Jagged Proteins , Signal Transduction/immunology , Spleen/immunology , Spleen/pathology
7.
Int Immunol ; 20(6): 763-73, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18381350

ABSTRACT

Notch2 and Delta-like 1 (Dll1) have been implicated in the development of marginal zone B (MZB) cells. In the present study, we characterized the expression and function of mouse Notch receptors and ligands in the spleen by using newly generated mAbs. Although Notch2 was expressed on both B and T cells in the spleen, the highest expression was observed on precursors of marginal zone B and MZB cells. Dll1 was expressed on macrophage and erythroblasts in the red pulp, but not on B cells or marginal zone macrophage. Administration of a blocking mAb against Dll1 not only blocked the development of MZB cells in juvenile mice but also gradually depleted the pre-established MZB cells in adult mice, indicating a critical role for Dll1 in the maintenance of MZB cells in the spleen of normal mice. Interestingly, Dll1 was not necessary for the maintenance of MZB cells in lupus-prone (NZB x NZW) F1 mice particularly after the onset of the disease, suggesting that the Dll1 independence may be a feature of dysregulated MZB cells producing auto-antibodies.


Subject(s)
Autoimmunity/immunology , B-Lymphocytes/immunology , Intracellular Signaling Peptides and Proteins/immunology , Intracellular Signaling Peptides and Proteins/metabolism , Membrane Proteins/immunology , Membrane Proteins/metabolism , Animals , Antibodies, Blocking/pharmacology , Autoantibodies/biosynthesis , B-Lymphocytes/metabolism , B-Lymphocytes/pathology , Cell Differentiation/immunology , Disease Models, Animal , Gene Expression Regulation/immunology , Homeostasis/immunology , Intracellular Signaling Peptides and Proteins/antagonists & inhibitors , Lupus Erythematosus, Systemic/immunology , Membrane Proteins/antagonists & inhibitors , Mice , Mice, Inbred NZB , Receptor, Notch2/immunology , Receptor, Notch2/metabolism , Spleen/immunology , Spleen/metabolism , Spleen/pathology
8.
J Immunol ; 180(3): 1954-61, 2008 Feb 01.
Article in English | MEDLINE | ID: mdl-18209094

ABSTRACT

Intraarticular gene transfer of cyclin-dependent kinase (CDK) inhibitors to suppress synovial cell cycling has shown efficacy in treating animal models of rheumatoid arthritis. Endogenous CDK inhibitors also modulate immune function via a CDK-independent pathway. Accordingly, systemic administration of small molecules that inhibit CDK may or may not ameliorate arthritis. To address this issue, alvocidib (flavopiridol), known to be tolerated clinically for treating cancers, and a newly synthesized CDK4/6-selective inhibitor were tested for antiarthritic effects. In vitro, they inhibited proliferation of human and mouse synovial fibroblasts without inducing apoptosis. In vivo, treatment of collagen-induced arthritis mice with alvocidib suppressed synovial hyperplasia and joint destruction, whereas serum concentrations of anti-collagen type II (CII) Abs and proliferative responses to CII were maintained. Treatment was effective even when therapeutically administered. Treated mice developed arthritis after termination of treatment. Thus, immune responses to CII were unimpaired. The same treatment ameliorated arthritis induced by K/BxN serum transfer to lymphocyte-deficient mice. Similarly, the CDK4/6-selective inhibitor suppressed collagen-induced arthritis. Both small-molecule CDK inhibitors were effective in treating animal models of rheumatoid arthritis not by suppressing lymphocyte function. Thus, the two small-molecule CDK inhibitors ameliorated arthritis models in a distinctive way, compared with other immunosuppressive drugs.


Subject(s)
Arthritis, Experimental/drug therapy , Arthritis, Rheumatoid/drug therapy , Cyclin-Dependent Kinase 4/therapeutic use , Cyclin-Dependent Kinase 6/therapeutic use , Cyclin-Dependent Kinases/antagonists & inhibitors , Flavonoids/therapeutic use , Piperidines/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Animals , Arthritis, Experimental/pathology , Arthritis, Rheumatoid/pathology , Autoantibodies/blood , Cell Proliferation/drug effects , Collagen Type II/immunology , Disease Models, Animal , Fibroblasts/drug effects , Flavonoids/pharmacology , Mice , Mice, Inbred Strains , Piperidines/pharmacology , Protein Kinase Inhibitors/pharmacology , Synovial Membrane/cytology , Synovial Membrane/drug effects , Treatment Outcome
9.
Arthritis Rheum ; 56(4): 1304-14, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17394136

ABSTRACT

OBJECTIVE: To establish a new murine model of polymyositis (PM) for the understanding of its pathologic mechanisms and the development of new treatment strategies. METHODS: C protein-induced myositis (CIM) was induced by a single immunization of recombinant human skeletal C protein in C57BL/6 mice, as well as in CD4-depleted, CD8-depleted, and mutant mice as controls. Some mice were treated with high-dose intravenous immunoglobulin (IVIG) after disease induction. Muscle tissues were examined histologically. RESULTS: In mice with CIM, inflammation was confined to the skeletal muscles. Histologic examination revealed a common pathologic feature of CIM and PM, involving abundant infiltration of CD8 and perforin-expressing cells in the endomysial site of the injured muscle. Suppression of myositis was achieved by depletion of both CD4 and CD8 T cells. Despite the development of serum anti-C protein antibodies in wild-type mice, severe myositis was induced in mice deficient in B cells. Induction of myositis was suppressed in interleukin-1alpha/beta (IL-1alpha/beta)-null mutant mice, but not in tumor necrosis factor alpha (TNFalpha)-null mutant mice. Use of IVIG, a treatment with proven efficacy in PM, suppressed CIM in the subgroup of treated mice. CONCLUSION: CIM mimics PM pathologically and clinically. Infiltration of CD8 T cells is the most likely mechanism of muscle injury, and IL-1, but not B cells or TNFalpha, is crucial in the development of CIM. IVIG has therapeutic effects in CIM, suggesting that the effects of IVIG are not mediated by suppression of antibody-mediated tissue injury. This murine model provides a useful tool for understanding the pathologic mechanisms of PM and for developing new treatment strategies.


Subject(s)
Carrier Proteins/immunology , Disease Models, Animal , Immunoglobulins, Intravenous/therapeutic use , Muscle, Skeletal/pathology , Polymyositis/pathology , Polymyositis/therapy , Animals , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/pathology , CD8 Antigens/metabolism , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/pathology , Female , Gene Silencing , Humans , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Mice, Knockout , Mice, Mutant Strains , Muscle, Skeletal/immunology , Muscle, Skeletal/metabolism , Polymyositis/immunology , Postural Balance/drug effects , Postural Balance/physiology , Recombinant Proteins , Running
10.
Proc Natl Acad Sci U S A ; 103(39): 14465-70, 2006 Sep 26.
Article in English | MEDLINE | ID: mdl-16980409

ABSTRACT

Genetic susceptibility to rheumatoid arthritis (RA) is associated with certain MHC class II molecules. To clarify the role of these determinants in RA, we generated the D1CC transgenic mouse that expressed genes involved in antigen processing and presentation by the MHC class II pathway in joints. The class II transactivator, which was transcribed from the rat collagen type II promoter and enhancer, directed the expression of these genes. In D1CC mice congenic for the H-2(q) (DBA/1) background, small amounts of bovine collagen type II in adjuvant induced reproducibly an inflammatory arthritis resembling RA. Importantly, these stimuli had no effect in DBA/1 mice. Eighty-nine percent of D1CC mice developed chronic disease with joint swelling, redness, and heat in association with synovial proliferation as well as pannus formation and mononuclear infiltration of synovial membranes. Granulomatous lesions resembling rheumatoid nodules and interstitial pneumonitis also were observed. As in patients with RA, anticyclic citrullinated peptide antibodies were detected during the inflammatory stage. Finally, joints in D1CC mice displayed juxtaarticular demineralization, severe joint space narrowing, and erosions, which led to ankylosis, but without the appearance of osteophytes. Thus, aberrant expression of MHC class II in joints facilitates the development of severe erosive inflammatory polyarthritis, which is very similar to RA.


Subject(s)
Arthritis, Rheumatoid/pathology , Gene Expression , Genes, MHC Class II/genetics , Joints/pathology , Animals , Arthritis, Experimental , Arthrography , Bone Density/physiology , Cattle , Collagen Type II/administration & dosage , Dose-Response Relationship, Drug , Forelimb/abnormalities , Forelimb/diagnostic imaging , Humans , Immunization , Inflammation , Joints/abnormalities , Joints/cytology , Lung Diseases, Interstitial/pathology , Mice , Mice, Inbred DBA , Mice, Transgenic , Rats
11.
Arthritis Rheum ; 54(7): 2074-83, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16802342

ABSTRACT

OBJECTIVE: It is known that the cyclin-dependent kinase inhibitor (CDKI) gene p21(Cip1) suppresses rheumatoid inflammation by down-modulating type I interleukin-1 receptor (IL-1RI) expression and inhibiting JNK activity. The purpose of this study was to determine whether CDK activity directly modulates the production of inflammatory molecules in patients with rheumatoid arthritis (RA). METHODS: Genes for the CDKIs p16(INK4a) and p18(INK4c), a constitutively active form of retinoblastoma (RB) gene product, cyclin D1, and CDK-4, were transferred into RA synovial fibroblasts (RASFs). RASFs were also treated with a synthetic CDK-4/6 inhibitor (CDK4I). Levels of matrix metalloproteinase 3 (MMP-3), monocyte chemoattractant protein 1 (MCP-1), and IL-1RI expression were determined by Northern blotting, real-time polymerase chain reaction analysis, and enzyme-linked immunosorbent assay. CDKIs were immunoprecipitated to reveal their association with JNK. RESULTS: Transfer of the p16(INK4a) and p18(INK4c) genes and CDK4I suppressed the production of MMP-3 and MCP-1. Unlike p21(Cip1), neither CDKI gene inhibited IL-1RI or JNK. The expression of MMP-3 was up-regulated when CDK-4 activity was augmented. This regulation functioned at the messenger RNA (mRNA) level in MMP-3, but not in MCP-1. Transfer of active RB suppressed the production of MMP-3 and MCP-1 without changing their mRNA levels. CONCLUSION: CDK-4/6 modulated the production of MMP-3 and MCP-1. MMP-3 production was regulated primarily at the mRNA level in an RB-independent manner, whereas MCP-1 production was controlled posttranscriptionally by RB. These results show that cell cycle proteins are associated with control of mediators of inflammation through multiple pathways.


Subject(s)
Arthritis, Rheumatoid/genetics , Arthritis, Rheumatoid/physiopathology , Chemokine CCL2/metabolism , Cyclin-Dependent Kinase 4/metabolism , Cyclin-Dependent Kinase 6/metabolism , Matrix Metalloproteinase 3/metabolism , Retinoblastoma Protein/physiology , Arthritis, Rheumatoid/pathology , Cell Proliferation , Cells, Cultured , Chemokine CCL2/genetics , Cyclin D1/genetics , Cyclin D1/metabolism , Cyclin-Dependent Kinase 4/antagonists & inhibitors , Cyclin-Dependent Kinase 4/genetics , Cyclin-Dependent Kinase 6/antagonists & inhibitors , Cyclin-Dependent Kinase 6/genetics , Cyclin-Dependent Kinase Inhibitor p16/genetics , Cyclin-Dependent Kinase Inhibitor p16/physiology , Cyclin-Dependent Kinase Inhibitor p18/genetics , Cyclin-Dependent Kinase Inhibitor p18/physiology , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p21/physiology , Fibroblasts/drug effects , Fibroblasts/metabolism , Fibroblasts/pathology , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , Humans , MAP Kinase Kinase 4/genetics , MAP Kinase Kinase 4/metabolism , Matrix Metalloproteinase 3/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Interleukin-1/genetics , Receptors, Interleukin-1/metabolism , Receptors, Interleukin-1 Type I , Retinoblastoma Protein/genetics , Synovial Membrane/drug effects , Synovial Membrane/metabolism , Synovial Membrane/pathology
13.
Arthritis Res ; 4 Suppl 3: S133-40, 2002.
Article in English | MEDLINE | ID: mdl-12110132

ABSTRACT

Genetic susceptibility to rheumatoid arthritis (RA), a common autoimmune disease, is associated with certain HLA-DR4 alleles. Treatments are rarely curative and are often tied to major side effects. We describe the development of a humanized mouse model wherein new, less toxic, vaccine-like treatments for RA might be pretested. This model includes four separate transgenes: HLA-DR*0401 and human CD4 molecules, a RA-related human autoantigenic protein (HCgp-39), and a T-cell receptor (TCRalphabeta) transgene specific for an important HCgp-39 epitope, eliciting strong Th1 responses in the context of HLA-DR*0401.


Subject(s)
Arthritis, Rheumatoid/genetics , Arthritis, Rheumatoid/physiopathology , Disease Models, Animal , Mice, Transgenic , Animals , Arthritis, Rheumatoid/immunology , Humans , Mice
SELECTION OF CITATIONS
SEARCH DETAIL
...